The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.b

Opportunistic pulmonary/systemic infections

Publications

Buonomo AR, Zappulo E, Viceconte G, Scotto R, Borgia G, Gentile I

Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis.

Expert opinion on drug safety. 2018;17(7):709-717

Cheson BD, Leonard JP

Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.

The New England journal of medicine. 2008;359(6):613-26

Meeuse JJ, Sprenger HG, van Assen S, Leduc D, Daenen SM, Arends JP, van der Werf TS

Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia.

Emerging infectious diseases. 2007;13(12):1942-3

Nosari A, Montillo M, Morra E

Infectious toxicity using alemtuzumab.

Haematologica. 2004;89(12):1415-9

Rieger K, Von Grünhagen U, Fietz T, Thiel E, Knauf W

Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?

Leukemia & lymphoma. 2004;45(2):345-9